Onset
Not established in humans.
Protocol / Research Dosing Guide
KPV Dosage Guide: Dosage Chart, Reconstitution and Safety
A source-gated KPV reference covering the 5 mg and 10 mg vial arithmetic, route comparisons and the laboratory and animal evidence that sits behind them.
Last reviewed September 16, 202616 minute readResearch information only
Level 2 — Animal and laboratory evidenceNo human dose-finding trialNot FDA approved
KPV Quick Start
KPV is a three-amino-acid peptide cut from the C-terminus of alpha-MSH and studied mainly in laboratory and animal inflammation work. It is small enough to be carried by the gut transporter PepT1, which is why oral and subcutaneous routes are both discussed. Unlike melanotan-type peptides it does not trigger pigmentation, because it skips melanocortin-receptor signalling.
Why researchers care
Anti-inflammatory signalling and gut-barrier research, particularly in IBD models
Class
Lysine-proline-valine tripeptide, the C-terminal fragment of alpha-MSH
Route reported
Oral, subcutaneous, topical and less commonly intranasal
Cycle length
Not established
Regulatory status
Not FDA approved
Loading supplier information
KPV Dosing Protocol and Schedule
The supplied source reports community planning around 200–500 mcg daily and provides calculation references: a 5 mg vial with 1 mL and a 10 mg vial with 2 mL both give 5,000 mcg/mL.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Community planning range | 200–500 mcg daily | Community reported |
| Oral route | Discussed for gut-focused research because of PepT1 transport | Animal and laboratory rationale |
| Subcutaneous route | Discussed for systemic inflammation research | Community reported |
| Topical route | Discussed for skin research | Community reported |
| Cycle length | Not established | Not established |
No completed human dose-finding trial has established a KPV amount, schedule, cycle or route. The values above are calculation examples and community-reported practice.
KPV Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label
KPV Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take KPV: Morning or Night?
Time of day?
Not established. No study compares administration times.
Once or split?
Community planning describes a daily total rather than a validated frequency.
With food?
Oral discussion centers on PepT1 transport rather than meal timing; no rule is established.
Missed amount?
No validated procedure exists.
KPV Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Oral | Discussed because PepT1 can transport a tripeptide | Human absorption is not established |
| Subcutaneous | The most common research-use format | No human pharmacokinetic study |
| Topical | Discussed for skin research | No human standard established |
| Intranasal | Occasionally described | No supporting evidence |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
KPV Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human pharmacokinetic study identified |
| Animal clearance | Short peptides of this size clear quickly | General pharmacology, not KPV-specific |
| Oral exposure | Not established | PepT1 transport is a mechanism, not a measured bioavailability |
| Frequency | Not established | Community planning only |
KPV Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Any route | 200 mcg | Daily planning example | Calculation reference | No |
| Any route | 300 mcg | Daily planning example | Calculation reference | No |
| Any route | 400 mcg | Daily planning example | Calculation reference | No |
| Any route | 500 mcg | Daily planning example | Calculation reference | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
KPV Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.5 mg | 0.1 mL | 10 units |
| 1 mg | 0.2 mL | 20 units |
| 1.5 mg | 0.3 mL | 30 units |
- 1.Confirm the milligram total on the vial label.
- 2.Record the exact bacteriostatic water volume added.
- 3.Clean the stopper with an alcohol swab.
- 4.Add liquid slowly down the vial wall.
- 5.Swirl gently until clear; do not shake.
- 6.A 5 mg vial with 1 mL and a 10 mg vial with 2 mL both give 5,000 mcg/mL.
- 7.At 5,000 mcg/mL, 200 mcg is 4 units, 300 mcg is 6 units, 400 mcg is 8 units and 500 mcg is 10 units on a U-100 syringe.
- 8.Label the concentration and preparation date, then refrigerate.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How KPV Works
Origin
KPV is the C-terminal tripeptide of alpha-MSH.
KPV Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved
- No completed human dose-finding trial has established a KPV dose, schedule, cycle or route.
- Evidence is laboratory and animal work, largely in inflammatory bowel disease models.
- KPV is not FDA approved.
- July 2026 meeting materials proposed against adding KPV free base and KPV acetate to the 503A Bulks List.
Who Should Avoid KPV?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Active autoimmune disease under treatment
Immune-signalling effects are not characterized in humans
Concurrent immunosuppressive medicines
No interaction studies
Known sensitivity to the product or excipients
Product-specific risk
KPV Side Effects, Risks and Safety
Injection-site reactionAnecdotal
Important limitation: No controlled incidence data.
Gastrointestinal upset with oral useAnecdotal
Important limitation: No controlled incidence data.
Allergic responseUnknown
Important limitation: No characterized human safety dataset.
Immune-signalling effectsAnimal and laboratory
Important limitation: Human relevance not established.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
KPV Timeline and Monitoring
Animal model windows
Study-specific and tied to the inflammation model used.
Monitoring
No validated monitoring schedule exists.
Stopping rules
Not established.
KPV Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Gut inflammation | Animal and laboratory | Level 2 | IBD models, not human outcomes |
| Systemic anti-inflammatory effect | Laboratory | Level 2 | No human trial |
| Skin inflammation | Laboratory and anecdotal | Level 2 or lower | No human standard |
| Pigmentation | Not applicable | Mechanistically excluded | KPV skips melanocortin signalling |
KPV Storage and Handling
Unreconstituted vial
Follow the product label; keep cool, dry and out of light.
Prepared vial
Refrigerate and protect from light.
Freezing
Repeated freeze-thaw cycles are avoided for peptide solutions.
Appearance
Cloudiness, discoloration or particles mean the solution should not be used.
KPV Troubleshooting
5 mg and 10 mg units look identical
They are, at the reference mixes: 5 mg with 1 mL and 10 mg with 2 mL both give 5,000 mcg/mL.
Oral and injectable amounts are compared directly
Human oral absorption is not established, so the two are not equivalent.
Solution appears cloudy
Stop and seek qualified product guidance.
Unexpected symptoms
Seek licensed clinical review.
Missed planned administration
No validated procedure exists.
KPV Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| KPV | Alpha-MSH C-terminal tripeptide | Anti-inflammatory laboratory and animal evidence | No pigmentation effect |
| Alpha-MSH | Full parent peptide | Melanocortin-receptor signalling | Causes pigmentation |
| BPC-157 | Separate repair-focused peptide | Different evidence base | Not interchangeable |
KPV Frequently Asked Questions
What is KPV?
A lysine-proline-valine tripeptide cut from the C-terminus of alpha-MSH.
Is KPV FDA approved?
No.
Is there a human dose?
No. No completed human dose-finding trial has established one.
Does KPV cause tanning?
No. It skips melanocortin-receptor signalling.
Why is oral use discussed?
KPV is small enough to be carried by the gut transporter PepT1.
What concentration does a 10 mg vial with 2 mL give?
5,000 mcg/mL.
How many units is 500 mcg at that concentration?
10 units on a U-100 syringe.
Is a cycle length established?
No.
What is its regulatory status?
Not FDA approved; July 2026 meeting materials proposed against adding KPV free base and acetate to the 503A Bulks List.
Are oral and injectable amounts interchangeable?
No. Human absorption is not established.
What does the calculator do?
Concentration and volume arithmetic only.
Sources and Research
Coverage source
1. KPV protocol coverage source
Supplied coverage source for the dosage chart, route comparison and vial arithmetic.
Open direct sourceAnimal research
2. KPV suppresses intestinal inflammation via PepT1 transport
Animal and cell research describing PepT1-mediated uptake and reduced colitis severity.
Open direct sourceLaboratory research
3. Anti-inflammatory activity of the alpha-MSH C-terminal tripeptide
Laboratory characterization of KPV anti-inflammatory signalling.
Open direct sourceMissing information flagged for review
- Human dose: Not established
- Human oral bioavailability: Not established
- Human half-life: Not established
- Validated cycle and rest period: Not established
- Human safety dataset: Not established